This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCart, J. A. Articles by Bartlett, D. L. Search for Related Content PubMed PubMed Citation Articles by McCart, J. A. Articles by Bartlett, D. L.

Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes

Surgery Branch, National Cancer Institute [J. A. M., J. L., Y. H., H. R. A., S. K. L., D. L. B.] and Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases [B. M.], NIH, Bethesda, Maryland 20892-1502, and Office of Laboratory Animal Resources, National Cancer Institute, Frederick, Maryland 21702 [J. M. W.]

We have demonstrated previously the oncolytic effects of a systemically delivered, replicating vaccinia virus. To enhance the tumor specificity of this vector, we have developed a combined thymidine kinase-deleted (TK-) and vaccinia growth factor-deleted (VGF-) vaccinia virus and investigated its properties in vitro and in vivo. The gene for enhanced green fluorescent protein (EGFP) was inserted into the TK locus of a VGF- vaccinia virus by homologous recombination creating a double-deleted mutant vaccinia virus (vvDD-GFP). Infection of resting and dividing NIH3T3 cells with vvDD-GFP yielded reduced viral recovery compared with wild-type (WT), TK-, or VGF- viruses from resting cultures but equivalent virus recovery from dividing cultures. Eight days after nude mice were injected i.p. with 10⁷ plaque-forming units (pfu) of WT, TK-, VGF-, or vvDD-GFP vaccinia virus, tissues and tumor were harvested for viral titer determination. No virus was recovered from the brains of mice injected with vvDD-GFP compared with the other viruses, which ranged from 130 to 28,000 pfu/mg protein; however, equivalent amounts were recovered from tumor. There was no toxicity from vvDD-GFP because nude mice receiving 10⁸ pfu of IP vvDD-GFP lived >100 days, whereas mice receiving WT, VGF-, or TK- virus had median survivals of only 6, 17, and 29 days, respectively. Similar results were seen when 10⁹ pfu of vvDD-GFP were given. Nude mice bearing s.c. murine colon adenocarcinoma (MC38) had significant tumor regression after treatment with 10⁹ pfu of systemic (i.p.) vvDD-GFP compared with control (mean tumor size, 180.71 ± 35.26 mm³ versus 2796.79 ± 573.20 mm³ 12 days after injection of virus). Our data demonstrate that a TK- and VGF- mutant vaccinia virus is significantly attenuated in resting cells in vitro and demonstrates tumor-specific replication in vivo. It is a promising vector for use in tumor-directed gene therapy, given its enhanced safety profile, tumor selectivity, and the oncolytic effects after systemic delivery.

This article has been cited by other articles:

				T. L.-A. Nguyen, H. Abdelbary, M. Arguello, C. Breitbach, S. Leveille, J.-S. Diallo, A. Yasmeen, T. A. Bismar, D. Kirn, T. Falls, et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis PNAS, September 30, 2008; 105(39): 14981 - 14986. [Abstract] [Full Text] [PDF]

				Q. Zhang, Y. A. Yu, E. Wang, N. Chen, R. L. Danner, P. J. Munson, F. M. Marincola, and A. A. Szalay Eradication of Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus Cancer Res., October 15, 2007; 67(20): 10038 - 10046. [Abstract] [Full Text] [PDF]

				M. M. Stanford, J. W. Barrett, S. H. Nazarian, S. Werden, and G. McFadden Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells J. Virol., February 1, 2007; 81(3): 1251 - 1260. [Abstract] [Full Text] [PDF]

				S. H. Thorne, R. S. Negrin, and C. H. Contag Synergistic antitumor effects of immune cell-viral biotherapy. Science, March 24, 2006; 311(5768): 1780 - 1784. [Abstract] [Full Text] [PDF]

				Z. S. Guo, A. Naik, M. E. O'Malley, P. Popovic, R. Demarco, Y. Hu, X. Yin, S. Yang, H. J. Zeh, B. Moss, et al. The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2 Cancer Res., November 1, 2005; 65(21): 9991 - 9998. [Abstract] [Full Text] [PDF]

				K. Suzuki, R. Alemany, M. Yamamoto, and D. T. Curiel The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses Clin. Cancer Res., November 1, 2002; 8(11): 3348 - 3359. [Abstract] [Full Text] [PDF]